The usefulness and wellbeing of Tofacitinib in the treatment of Alopecia Areata

Introduction: Treatment options for alopecia areata are limited and often inadequate but the use of an oral Janus kinase inhibitor such as Tofacitinib is considered promising treatment areata. Objective: To evaluate usefulness wellbeing in Materials Methods: This clinical trial was conducted at Department Dermatology Venereology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka during July 2018 to December 2019. A total 45 patients with patchy (at least> 50% scalp involvement), form totalis universalis were treated 5mg twice daily 6 months. Clinical testing performed on basis Severity Alopecia Tool Score (SALT). Results: The average age 33.00 ± 13.1 years. For them 40.0% patients' less than 20 In addition, 26 (57.8%) infected with> involvement, 11 (24.4%) had Alopeciatotalis 8 (17.8%) universalis. duration illness 1.2 0.6 follow-up revealed that among 15.4% a gradual growth 84.6% re-growth full hair. Of totalis, 27.3% partial rejuvenation 72.7% hair universalis, 37.5% increase 62.5% recurrence perfect terms well-being, 34 (75.6%) did not experience side effects experienced 18.2% nausea, headache 9.1% high infection respiratory tract (URTI). Conclusion: by tofacitinib, inhibitors effective, safe sound JAFMC Bangladesh. Vol 18, No 1 (June) 2022: 43-47